672 related articles for article (PubMed ID: 34116900)
21. Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Patients with Peritoneal Metastases from Endometrial Cancer.
Cornali T; Sammartino P; Kopanakis N; Christopoulou A; Framarino Dei Malatesta M; Efstathiou E; Spagnoli A; Ciardi A; Biacchi D; Spiliotis J
Ann Surg Oncol; 2018 Mar; 25(3):679-687. PubMed ID: 29282600
[TBL] [Abstract][Full Text] [Related]
22. Benefit of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy in patients with isolated peritoneal metastases from colorectal cancer.
Piso P; Stierstorfer K; Gerken M; Klinkhammer-Schalke M
Int J Colorectal Dis; 2018 Nov; 33(11):1559-1567. PubMed ID: 30132068
[TBL] [Abstract][Full Text] [Related]
23. Peritoneal carcinomatosis index predicts survival in colorectal patients undergoing HIPEC using oxaliplatin: a retrospective single-arm cohort study.
Burnett A; Lecompte MA; Trabulsi N; Dubé P; Gervais MK; Trilling B; Cloutier AS; Sideris L
World J Surg Oncol; 2019 May; 17(1):83. PubMed ID: 31092250
[TBL] [Abstract][Full Text] [Related]
24. Long-term survival after hyperthermic intraperitoneal chemotherapy using mitomycin C or oxaliplatin in colorectal cancer patients with synchronous peritoneal metastases: A nationwide comparative study.
Bakkers C; van Erning FN; Rovers KP; Nienhuijs SW; Burger JW; Lemmens VE; Aalbers AG; Kok NF; Boerma D; Brandt AR; Hemmer PH; van Grevenstein WM; de Reuver PR; Tanis PJ; Tuynman JB; de Hingh IH
Eur J Surg Oncol; 2020 Oct; 46(10 Pt A):1902-1907. PubMed ID: 32340819
[TBL] [Abstract][Full Text] [Related]
25. Peritoneal carcinomatosis in colorectal cancer: Defining predictive factors for successful cytoreductive surgery and hyperthermic intraperitoneal chemotherapy - A pilot study.
Mahmoud AM; Ismail YM; Hussien A; Debaky Y; Ahmed IS; Mikhael HSW; Moneer M
J Egypt Natl Canc Inst; 2018 Dec; 30(4):143-150. PubMed ID: 30472198
[TBL] [Abstract][Full Text] [Related]
26. Towards Equal Access to Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy and Survival in Patients with Isolated Colorectal Peritoneal Metastases: A Nationwide Population-Based Study.
van der Ven RGFM; van den Heuvel TBM; Rovers KPB; Nienhuijs SW; Boerma D; van Grevenstein WMU; Hemmer PHJ; Kok NFM; Madsen EVE; de Reuver P; Tuynman JB; van Erning FN; de Hingh IHJT
Ann Surg Oncol; 2024 Jun; 31(6):3758-3768. PubMed ID: 38453767
[TBL] [Abstract][Full Text] [Related]
27. Neoadjuvant chemotherapy with bevacizumab may improve outcome after cytoreduction and hyperthermic intraperitoneal chemoperfusion (HIPEC) for colorectal carcinomatosis.
Ceelen W; Van Nieuwenhove Y; Putte DV; Pattyn P
Ann Surg Oncol; 2014 Sep; 21(9):3023-8. PubMed ID: 24756812
[TBL] [Abstract][Full Text] [Related]
28. Evolution of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: 8-Year Single-Institutional Experience.
Narasimhan V; Britto M; Pham T; Warrier S; Naik A; Lynch AC; Michael M; Tie J; Ramsay R; Heriot A
Dis Colon Rectum; 2019 Oct; 62(10):1195-1203. PubMed ID: 31490828
[TBL] [Abstract][Full Text] [Related]
29. Colorectal peritoneal carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: the experience of a tertiary Asian center.
Teo MC; Ching Tan GH; Lim C; Chia CS; Tham CK; Soo KC
Asian J Surg; 2015 Apr; 38(2):65-73. PubMed ID: 25059814
[TBL] [Abstract][Full Text] [Related]
30. Long-term survival outcomes following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal metastasis of hepatocellular carcinoma patients.
Yan G; Zhang K; Yan L; Zhang Y
World J Surg Oncol; 2024 May; 22(1):144. PubMed ID: 38822337
[TBL] [Abstract][Full Text] [Related]
31. Development of a prediction model for recurrence in patients with colorectal peritoneal metastases undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.
Dietz MV; Hannink G; Said I; van der Zant FA; van de Vlasakker VCJ; Brandt-Kerkhof ARM; Verhoef C; Bremers AJA; de Wilt JHW; Hemmer PHJ; de Hingh IHJT; de Reuver PR; Madsen EVE
Eur J Surg Oncol; 2024 Jun; 50(6):108294. PubMed ID: 38583215
[TBL] [Abstract][Full Text] [Related]
32. Outcomes of Stable Lung Colorectal Metastases on Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
Pantelis A; Ben-Yaacov A; Adileh M; Schtrechman G; Shacham-Shmueli E; Boursi B; Margalit O; Halpern N; Mor E; Assaf D; Maximiliano K; Nissan A; Laks S
J Gastrointest Surg; 2022 Aug; 26(8):1724-1731. PubMed ID: 35768716
[TBL] [Abstract][Full Text] [Related]
33. More Synchronous Peritoneal Disease but Longer Survival in Younger Patients with Carcinomatosis from Colorectal Cancer Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
Solomon D; DeNicola NL; Feferman Y; Bekhor E; Reppucci ML; Feingold D; Aycart SN; Magge DR; Golas BJ; Labow DM; Sarpel U
Ann Surg Oncol; 2019 Mar; 26(3):845-851. PubMed ID: 30643994
[TBL] [Abstract][Full Text] [Related]
34. Curative cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis and synchronous resectable liver metastases arising from colorectal cancer.
Lorimier G; Linot B; Paillocher N; Dupoiron D; Verrièle V; Wernert R; Hamy A; Capitain O
Eur J Surg Oncol; 2017 Jan; 43(1):150-158. PubMed ID: 27839895
[TBL] [Abstract][Full Text] [Related]
35. Prolonged perioperative thoracic epidural analgesia may improve survival after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: A comparative study.
Lorimier G; Seegers V; Coudert M; Dupoiron D; Thibaudeau E; Pouplin L; Lebrec N; Dubois PY; Dumont F; Guérin-Meyer V; Capitain O; Campone M; Wernert R
Eur J Surg Oncol; 2018 Nov; 44(11):1824-1831. PubMed ID: 30213715
[TBL] [Abstract][Full Text] [Related]
36. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal peritoneal metastases: analysis of short- and long-term outcomes.
Rosa F; Galiandro F; Ricci R; Di Miceli D; Quero G; Fiorillo C; Cina C; Alfieri S
Langenbecks Arch Surg; 2021 Dec; 406(8):2797-2805. PubMed ID: 34661754
[TBL] [Abstract][Full Text] [Related]
37. Retrospective Evaluation of the Prognostic Value of Histological Growth Pattern in Patients with Colorectal Peritoneal Metastases Undergoing Curative-Intent Cytoreductive Surgery.
Kamdem L; Asmar AE; Demetter P; Zana IC; Khaled C; Sclafani F; Donckier V; Vermeulen P; Liberale G
Ann Surg Oncol; 2024 Jun; 31(6):3778-3784. PubMed ID: 38491312
[TBL] [Abstract][Full Text] [Related]
38. Neoadjuvant systemic and hyperthermic intraperitoneal chemotherapy combined with cytoreductive surgery for gastric cancer patients with limited peritoneal metastasis: a prospective cohort study.
Yu P; Ye Z; Dai G; Zhang Y; Huang L; Du Y; Cheng X
BMC Cancer; 2020 Nov; 20(1):1108. PubMed ID: 33198674
[TBL] [Abstract][Full Text] [Related]
39. A novel treatment protocol with 6 cycles of neoadjuvant chemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in stage III primary ovarian cancer.
Marrelli D; Petrioli R; Cassetti D; D'Ignazio A; Marsili S; Mazzei MA; Lazzi S; Roviello F
Surg Oncol; 2021 Jun; 37():101523. PubMed ID: 33545658
[TBL] [Abstract][Full Text] [Related]
40. Cytoreductive surgery (CRS) with hyperthermic intraoperative peritoneal chemotherapy (HIPEC) versus standard of care (SoC) in people with peritoneal metastases from colorectal, ovarian or gastric origin: protocol for a systematic review and individual participant data (IPD) meta-analyses of effectiveness and cost-effectiveness.
Gurusamy K; Vale CL; Pizzo E; Bhanot R; Davidson BR; Mould T; Mughal M; Saunders M; Aziz O; O'Dwyer S
BMJ Open; 2020 May; 10(5):e039314. PubMed ID: 32404398
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
